07:23 AM EDT, 05/05/2025 (MT Newswires) -- BioCryst Pharmaceuticals ( BCRX ) reported Monday a breakeven in Q1, compared with a net loss of $0.17 per diluted share a year earlier.

Analysts polled by FactSet expected a GAAP loss of $0.07.

Revenue for the quarter ended March 31 was $145.5 million, up from $92.8 million a year earlier.

Analysts polled by FactSet expected $127.8 million.

The company said it now expects to deliver net income and positive cash flows for full year 2025, compared with its previous outlook for next year.

BioCryst shares were up nearly 17% in recent premarket activity.